+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
3 Aug 2015

Hetero launches Roche’s Rituximab biosimilar ‘Maball’ in India

Hetero Group has launched of its biosimilar ‘Rituximab’ under the brand name Maball in India.
It will be marketed and distributed by Hetero Healthcare Limited, a group company of Hetero.
The launch of biosimilar Rituximab will provide a much needed access to patients in India suffering with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia (CLL). Rituximab is recommended as the first-line treatment for NHL and is available in a single dose vial with two strengths – 100mg/10ml and 500mg/50ml.
Commenting on the launch, Hetero Group CMD Bandi Parthasaradhi Reddy said: “The launch of Maball strengthens Hetero’s position in the biosimilar market, and has enabled the company to join select biotech companies with the capability to develop, manufacture and commercialise complex monoclonal antibodies (MAB’s).”
“Biosimilars is one of the key strategic business areas for Hetero. We have invested in biosimilars and will introduce more biosimilar MAB’s in the future. We also have plans to introduce affordable biosimilar Rituximab into key markets outside India through our partners,” he added.

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.